Warfarin Toxicity and Individual Variability—Clinical Case
Open Access
- 28 October 2010
- Vol. 2 (11), 2584-2592
- https://doi.org/10.3390/toxins2112584
Abstract
Warfarin is a widely used anticoagulant in the treatment and prevention of thrombosis, in the treatment for chronic atrial fibrillation, mechanical valves, pulmonary embolism, and dilated cardiomyopathy. It is tasteless and colorless, was used as a poison, and is still marketed as a pesticide against rats and mice. Several long-acting warfarin derivatives—superwarfarin anticoagulants—such as brodifacoum, diphenadione, chlorophacinone, bromadiolone, are used as pesticides and can produce profound and prolonged anticoagulation. Several factors increase the risk of warfarin toxicity. However, polymorphisms in cytochrome P450 genes and drug interactions account for most of the risk for toxicity complications. Each person is unique in their degree of susceptibility to toxic agents. The toxicity interpretation and the health risk of most toxic substances are a subject of uncertainty. Genetically determined low metabolic capacity in an individual can dramatically alter the toxin and metabolite levels from those normally expected, which is crucial for drugs with a narrow therapeutic index, like warfarin. Personalized approaches in interpretation have the potential to remove some of the scientific uncertainties in toxicity cases.Keywords
This publication has 44 references indexed in Scilit:
- Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism of S-WarfarinChemical Research in Toxicology, 2010
- Pharmacogenetics of WarfarinAnnual Review of Medicine, 2010
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysisAlimentary Pharmacology & Therapeutics, 2006
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarinJournal of the American College of Surgeons, 2002
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Effect of Sertraline on Protein Binding of WarfarinClinical Pharmacokinetics, 1997
- Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, CaliforniaPharmacogenetics, 1996